Investor Presentaiton
Initiatives Related to Profit Growth for Current Business and
Products in Japan
Enhance product portfolio
VANFLYTAⓇ Anti-Cancer Agent /FLT3 Inhibitor
➤ Obtained partial change approval for acute myeloid leukemia (AML) 1L therapy in May 2023
Changed from "relapsed/refractory FLT3-ITD positive AML" to "FLT3-ITD positive AML"
Daiichi-Sankyo
TARLIGEⓇ Orally Disintegrating Tablet
Pain Treatment
➤ Launched in May 2023
100線
100
100m
OITUSL
U-HOD 2.5mg
Tarlige OD 2.5mg
タリージェOD錠5mg
タリージェOD錠10mg
ROMIUMONE
OM/U
Tarlige
OD 5mg
Tarlige
OD 10mg
mirogan
mirogain
miregadalin
神經障害性所痛治療劑
9U-BIODE 15mg
ミロガンベシル酸製剤
Tarlige
mirogabalin
1002
OD 15mg
Enhance transformation into a profit structure focused on patented drugs
Stock Transfer of DAIICHI SANKYO ESPHA CO., LTD. (Concluded an agreement in May 2023)
➤ Transferee: Qol Holdings Co., Ltd.
Consideration for transfer: 25.0 Bn JPY
Date of transfer (planned) :
October 1, 2023 (30% of the shares held by the Company), April 1, 2024 (21% of the shares held by the Company)
The date of execution of the transfer of the remaining 49% of the Company's shares will be determined by separate negotiation.
14View entire presentation